openPR Logo
Press release

Meakin Metabolic Care Launches Metabolic Health Program for Individuals in Cancer Remission

11-25-2025 04:34 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Meakin Metabolic Care Launches Metabolic Health Program

Meakin Metabolic Care (MMC), a physician-led telehealth practice founded by board-certified radiation oncologist Dr. Charles Meakin, has launched a new metabolic health program aimed at supporting individuals in cancer remission. The program is designed for people who have completed cancer treatment and want a structured, science-driven path to strengthen their metabolic health and support their long-term wellness.

Meakin Metabolic Care [https://meakinmetaboliccare.com/] was founded by Dr. Meakin after more than three decades of experience caring for cancer patients. Over the years, he saw a consistent theme: patients needed more than traditional oncology alone. They needed metabolic guidance, lifestyle support, and a structured path to rebuild their health, not just during treatment, but long after.

MMC officially launched as a telehealth practice to fill this gap, offering evidence-based metabolic optimization programs for individuals looking to improve inflammation, insulin resistance, mitochondrial health, and overall metabolic function. What began as a focused service for cancer prevention and management quickly grew as patients sought ongoing support for long-term wellness.

Today, MMC provides three core service lines:

*
Cancer Prevention: metabolic optimization for individuals at risk

*
Cancer Management: support during active treatment

*
Cancer Remission: the Remission Metabolic Optimization Protocol (R-MOP)

The new metabolic health program for people in cancer remission is delivered through R-MOP, a subscription-based protocol designed specifically for individuals who have completed cancer treatment and want a structured, science-driven path for metabolic support and long-term wellness.

The R-MOP program includes a comprehensive intake and physician consultation to establish a detailed metabolic baseline. Participants receive a personalized plan supported by biomarker testing at baseline and then every six months. The protocol incorporates low-dose, repurposed medications when appropriate, targeted supplements, and lifestyle optimization to support mitochondrial health, inflammation reduction, insulin sensitivity, sleep quality, and nutrient density.

Ongoing support is a major pillar of the program. Participants receive clinical team check-ins, secure messaging access, and clear guidance that helps them stay consistent and encouraged. Rather than overwhelming survivors with complex regimens, MMC emphasizes clarity, structure, and realistic implementation.

"We created the Remission Metabolic Optimization Protocol (R-MOP) to help people in remission feel empowered rather than vulnerable," said Dr. Charles Meakin, founder of Meakin Metabolic Care. "After years of treating cancer patients, I've seen how much metabolic recovery matters. Survivors deserve a system that gives them tools, not just hope. R-MOP is designed to help them build resilience step-by-step."

The service uses a simple monthly subscription model. Medications and supplements are billed separately to maintain transparency and flexibility. MMC clearly states that R-MOP is not intended to replace oncology care; rather, it complements standard follow-up plans by strengthening the metabolic foundation that supports long-term well-being.

Every program at Meakin Metabolic Care is delivered through a physician-led, highly personalized, telehealth-based model that incorporates biomarker tracking, repurposed medications when appropriate, targeted supplementation, lifestyle adjustments, and ongoing clinical guidance.

The launch of this remission-focused metabolic health program reflects MMC's continued focus on helping individuals move from surviving to pursuing long-term wellness with structured, medically guided support.

For more information about the program and services, visit: https://meakinmetaboliccare.com/

Email: support@MeakinMetabolicCare.com

Phone: (646) 389 4012

MMC can also be found on:

Facebook: https://www.facebook.com/profile.php?id=61574197902100

LinkedIn: https://www.linkedin.com/company/meakin-metabolic-care

YouTube: https://www.youtube.com/@chuckmeakin375

About Meakin Metabolic Care

Meakin Metabolic Care is a physician-led telehealth metabolic medicine practice dedicated to evidence-based, proactive health optimization. MMC offers metabolic optimization programs designed to improve inflammation, insulin resistance, mitochondrial health, and overall metabolic function. The practice provides three core service lines: Cancer Prevention, Cancer Management, and Cancer Remission through the Remission Metabolic Optimization Protocol (R-MOP). MMC serves patients across the country with personalized care, clear protocols, and a mission to empower individuals to take control of their metabolic future.

Media Contact
Company Name: Meakin Metabolic Care
Contact Person: Dr. Charles J. Meakin, MD, MHA, MS
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=meakin-metabolic-care-launches-metabolic-health-program-for-individuals-in-cancer-remission]
Phone: (646) 389 4012
City: Fernandina
State: Florida
Country: United States
Website: http://meakinmetaboliccare.com

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Meakin Metabolic Care Launches Metabolic Health Program for Individuals in Cancer Remission here

News-ID: 4286016 • Views:

More Releases from ABNewswire

Red Teaming vs Penetration Testing: Understanding the Difference
Red Teaming vs Penetration Testing: Understanding the Difference
Image: https://www.abnewswire.com/upload/2025/12/bc1e8a773c50dd0c9305d06207de098f.jpg The topic of red teaming vs penetration testing often creates confusion among security teams, decision-makers and technical stakeholders. Both approaches aim to uncover weaknesses, yet they work in very different ways. Many organisations rely on one method thinking it covers the role of the other. This misunderstanding can lead to gaps in visibility, unclear expectations and misplaced confidence. A clearer view of pentest vs red team helps organisations make better
Suburban Solutions Moving Announces New West Chester, PA Location to Strengthen Regional Presence
Suburban Solutions Moving Announces New West Chester, PA Location to Strengthen …
West Chester, PA - Suburban Solutions [https://suburbansolutions.com/], a highly trusted and fast-growing moving company serving the Greater Philadelphia and Washington, DC regions, is proud to announce the opening of its newest location at 1271 Upton Cir, West Chester, PA 19380. This expansion marks an important step in the company's ongoing mission to provide dependable and accessible relocation support to more communities across Pennsylvania. With this new branch, Suburban Solutions Moving aims
LSLONG Launches New Premium Custom Polo Shirt Collection with Full OEM & ODM Support for Global Brands
12-12-2025 | Sports
ABNewswire
LSLONG Launches New Premium Custom Polo Shirt Collection with Full OEM & ODM Sup …
Shenzhen LSLONG Garments Co., Ltd., a global leader in apparel manufacturing, has officially unveiled its new Premium Custom Polo Shirt [https://www.lslt-shirt.com/polo-shirt-categories/] Collection, combining advanced fabrics, innovative designs, and end-to-end customization solutions. This launch underscores LSLONG's 25 years of experience delivering high-quality OEM and ODM apparel services to brands across more than 50 countries. The collection aims to empower brands with versatile, stylish, and performance-driven Polo shirts while providing comprehensive support
Arteestry Creations Plus Brings Unique Customizable Designs to Over 50 Product Categories With Cross-Product Flexibility and Licensed Collections
Arteestry Creations Plus Brings Unique Customizable Designs to Over 50 Product C …
Arteestry Creations Plus offers creative custom designs across an extensive range of products from apparel to home goods to magnets, serving customers seeking personalized items for holidays, special occasions, and everyday use. The growing e-commerce brand combines artistic creativity with broad product versatility, featuring licensed collections from Disney, Pixar, Marvel, and Star Wars alongside original designs that can be applied across different product types upon customer request. Arteestry Creations Plus has

All 5 Releases


More Releases for Metabolic

Evolving Market Trends In The Metabolic Biomarker Testing Industry: Advancements …
The Metabolic Biomarker Testing Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories]. What Is the Expected Metabolic Biomarker Testing Market Size During the Forecast Period? The market size for metabolic biomarker testing has seen considerable growth in the past few years. The market is predicted to
Prediabetes Market: Advancing Early Interventions for Metabolic Health
𝐆𝐥𝐨𝐛𝐚𝐥 𝐏𝐫𝐞𝐝𝐢𝐚𝐛𝐞𝐭𝐞𝐬 𝐌𝐚𝐫𝐤𝐞𝐭 𝐒𝐞𝐭 𝐭𝐨 𝐑𝐞𝐚𝐜𝐡 𝐔𝐒𝐃 𝟓𝟗𝟗.𝟑𝟒 𝐌𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟑, 𝐆𝐫𝐨𝐰𝐢𝐧𝐠 𝐚𝐭 𝐚 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟕.𝟏𝟓% The prediabetes market is experiencing significant growth as the world faces an increasing burden of metabolic disorders. Valued at USD 322.14 million in 2024, the market is projected to expand to USD 599.34 million by 2033, reflecting a CAGR of 7.15%. 𝐓𝐡𝐞 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐨𝐟 𝐭𝐡𝐢𝐬 𝐬𝐚𝐦𝐩𝐥𝐞 𝐑𝐞𝐩𝐨𝐫𝐭 𝐇𝐞𝐫𝐞: - https://www.astuteanalytica.com/request-sample/prediabetes-market With 470 million individuals globally diagnosed with
Metabolic Testing Market - Unleash Your Body's Potential: Metabolic Testing for …
Newark, New Castle, USA - new report, titled Metabolic Testing Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Metabolic Testing market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Metabolic Testing market. The report offers an overview of the market, which
Comprehensive Metabolic Panel Testing Market Size
The findings reviewed by GME stated that the Global Comprehensive Metabolic Panel Testing Market will grow from USD 11.5 billion in 2021, to USD 13.8 billion in 2026 with a CAGR value of 7.5%. Factors like the rising prevalence of chronic diseases, increasing prevalence of Covid-19 and increasing patients, technological advancements, increasing disposable income, growing geriatric population, emphasis on early diagnosis and treatment are expected to support the growth of
Therapeutic Proteins for Metabolic Disorders Treatment Market is Driven by Incre …
Therapeutic Proteins for Metabolic Disorders Treatment Market: Introduction Therapeutic proteins are proteins which are engineered in a laboratory for pharmaceutical use. Therapeutic proteins are used as a personalized treatment approach which supports a precisely targeted therapeutic process by making up for the deficiency of an essential protein. Therapeutic proteins are deliberately adjusted to increase their clinical potential which is followed by enhancements derived from protein or glycol engineering, Fc fusion, or conjugation
Inherited Metabolic Disorders Market Comprehensive Survey 2025
Global Inherited Metabolic Disorders Market: Overview Globally, IMD affects nearly one in every 2,500 to 5,000 individuals with nearly 300 to 600 new cases found in the U.K., according to Public Health Genetics U.K. The specificity and high risk affinity of IMD varies from disorder to disorder, with some disorders like familial cylomicronemia being closely associated with Caucasians and others like porphyria being recoded largely among African Americans. These metabolic